Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

PROCEPT BioRobotics (PRCT) Cost of Revenue (2020 - 2025)

PROCEPT BioRobotics (PRCT) has disclosed Cost of Revenue for 6 consecutive years, with $30.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Cost of Revenue rose 22.41% to $30.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $111.8 million, a 27.95% increase, with the full-year FY2025 number at $111.8 million, up 27.95% from a year prior.
  • Cost of Revenue was $30.1 million for Q4 2025 at PROCEPT BioRobotics, up from $29.3 million in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $30.1 million in Q4 2025 to a low of $3.7 million in Q1 2021.
  • A 5-year average of $16.0 million and a median of $15.5 million in 2023 define the central range for Cost of Revenue.
  • Peak YoY movement for Cost of Revenue: surged 133.03% in 2022, then grew 10.02% in 2024.
  • PROCEPT BioRobotics' Cost of Revenue stood at $5.6 million in 2021, then soared by 133.03% to $13.1 million in 2022, then surged by 70.41% to $22.3 million in 2023, then grew by 10.02% to $24.6 million in 2024, then rose by 22.41% to $30.1 million in 2025.
  • Per Business Quant, the three most recent readings for PRCT's Cost of Revenue are $30.1 million (Q4 2025), $29.3 million (Q3 2025), and $27.4 million (Q2 2025).